PBLA — Panbela Therapeutics, Inc.
$0.00
+$0.00 (+0.00%)
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Market Cap
$970.00
Forward P/E
-0.0x
52-Week Range
N/A
PBLA Price History
Revenue vs. Net Income
$0
Revenue · FY2023
Annual. Net margin is shown under each year.
Free Cash Flow
-$25.2M
FCF · FY2023
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-5219.6%
ROCE · FY2023 (approx.)
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.7x
Assets ÷ liabilities · FY2023
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+6114.5%
Dilution · FY2023
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
